DNA content and Ks8.12 binding of the psoriatic lesion during treatment with the vitamin D3 analogue MC903 and betamethasone

Br J Dermatol. 1990 Sep;123(3):291-5. doi: 10.1111/j.1365-2133.1990.tb06287.x.

Abstract

Twenty patients with psoriasis were treated with the vitamin D3 analogue MC903 and betamethasone ointment in a double-blind trial with a left-right comparison. In addition to the clinical severity scores, Ks8.12 binding which detects keratin 16 expression and the DNA synthesis were quantified using flow cytometry. Both markers decreased significantly with treatment, but remained above the normal range even in those who had total clearance of the lesions. Treatment with MC903 with regard to Ks8.12 binding was significantly better than with betamethasone.

Publication types

  • Clinical Trial
  • Comparative Study
  • Controlled Clinical Trial

MeSH terms

  • Adult
  • Aged
  • Antibodies, Monoclonal / metabolism
  • Betamethasone / therapeutic use*
  • Calcitriol / analogs & derivatives*
  • Calcitriol / therapeutic use
  • DNA / analysis*
  • Double-Blind Method
  • Female
  • Fluorescent Antibody Technique
  • Humans
  • Keratins / immunology
  • Keratins / metabolism*
  • Male
  • Middle Aged
  • Psoriasis / drug therapy*
  • Psoriasis / metabolism
  • Skin / metabolism

Substances

  • Antibodies, Monoclonal
  • calcipotriene
  • Keratins
  • DNA
  • Betamethasone
  • Calcitriol